Cedo Reveals Roadmap for Sustainable Business Growth
20.9.2021 10:00:00 EEST | Business Wire | Press release
Cedo, one of Europe’s largest manufacturers of recycled plastic waste bags has today revealed its Roadmap for Sustainable Business Growth. The plan is built on three pillars: People, Planet and Products and comes with targets designed to protect the earth’s resources while attracting and nurturing talent within the business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005048/en/
Cedo CEO, Rik De Vos, says “Cedo is proud of our contribution to achieving the goals of sustainable business development outlined by the UN” (Photo: Business Wire)
“Our plan has been built with deep engagement from all the employees within our company,” says Rik De Vos, CEO of Cedo. “The journey to circularity will not be easy, but I have seen an immediate shift in decision making, and prioritisation of actions now that we are a purpose-led business. We are actively contributing to European and UK legislative debate to accelerate this transformation, while articulating and communicating proactively and transparently. A dream has been turned into a great journey and it pleases me enormously to see the response from everybody on our ambition.”
People
To better serve customers and employees, Cedo is committing to become positively involved in its communities in the seven countries in which it operates, investing in them both as an employer and community member while actively supporting local environmental, health and wellness projects.
With its industry-leading focus on sustainability and rewarding career and development opportunities, Cedo hopes to attract fresh and diverse talent to join its two thousand-strong workforce who are as committed to environmental sustainability as they are to innovation. “We recognise that our economic growth as a business can only be delivered by valued colleagues and communities, high quality products and a healthy planet. Our pillars are aligned to these beliefs. Real success can only come from delivering progress in all three areas,” De Vos said.
Planet
For planet, the business has committed to achieving climate neutrality across its global operations by 2030, increasing its use of renewable energy and improving energy efficiency usage.
Cedo will also improve its stewardship of water, with clear monitoring and improvement plans while reducing the overall water consumption in its operations. The business aims to send zero waste to landfill and has already achieved this target this year in the UK.
Product
To achieve circularity, Cedo has pledged to use only recycled, recyclable or sustainable materials for both packaging and product design. “We will use the Ellen MacArthur Foundation’s Circulytics measurement tool, transparently tracking its progress to become a circular business,” says Ton Emans, Director of Recycling at Cedo and President of Plastics Recyclers Europe. “We’ve been members of the Ellen MacArthur Foundation and participants of the New Plastics Economy initiative since its inception in 2016 and by working together we are confident that we can transition from a linear to a circular business model over the next few years.”
Working with customers in 34 countries and listening to their needs, Cedo is aiming to dramatically reduce plastics in its products and focus better on the use of raw materials through its eco-design process, selecting the appropriate raw material for each product and its intended life cycle. Going forward, the business will only purchase from suppliers which meet its ethical, environmental and social standards.
All of these steps that Cedo is taking towards sustainable business growth will be measured and shared in a new, fully transparent Grow With Purpose report, released every year.
Supporting nine of the United Nations Sustainable Development Goals
As well as outlining its approach to doing business, Cedo’s Roadmap for Sustainable Business Growth explains how it will work towards nine of the United Nations Sustainable Development Goals. These are Goal 3, Good Health and Well-Being; Goal 5, Gender Equality; Goal 8, Decent Work and Economic Growth; Goal 9, Industry, Innovation and Infrastructure; Goal 12, Responsible Consumption and Production; Goal 13, Climate Action; Goal 14, Life Below Water; Goal 15, Life On Land and Goal 16, Peace, Justice and Strong Institutions.
In July 2021, Cedo announced that it is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005048/en/
Contact information
For further information please contact Miki Haines-Sanger on +44 7900 690 574 / miki@goldengoosepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
